A monoclonal antibody against TNF alpha, a powerful promoter of inflammation.

Institution:

New York University School of Medicine

Researchers:

Jan Vilcek, MD, PhD, NYU School of Medicine

Impact:

Collaborating with the biotechnology company Centocor, Dr. Vilcek helped to develop the biologic drug known commercially as Remicade. To date,¬†Remicade has been used to treat over a million patients worldwide for conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, plaque psoriasis, and ulcerative colitis.

Timeline:

1989